Twist Bioscience Corp
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands except per share data) | September 30, 2025 | September 30, 2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $183,049 | $226,316 |
| Short-term investments | 49,385 | 50,083 |
| Accounts receivable, net [1] | 57,019 | 34,903 |
| Inventories | 28,309 | 24,078 |
| Prepaid expenses and other current assets [2] | 15,204 | 11,396 |
| Total current assets | $332,966 | $346,776 |
| Property and equipment, net | 102,283 | 102,520 |
| Operating lease right-of-use assets | 49,377 | 58,829 |
| Investment in equity securities [3] | 54,337 | 1,525 |
| Goodwill | 82,195 | 85,811 |
| Intangible assets, net | 13,425 | 14,478 |
| Restricted cash, non-current | 2,376 | 2,816 |
| Other non-current assets [4] | 4,902 | 1,568 |
| Total assets | $641,861 | $614,323 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,094 | $1,630 |
| Accrued expenses | 23,053 | 15,104 |
| Accrued compensation | 31,288 | 33,650 |
| Current portion of operating lease liability | 13,822 | 14,805 |
| Other current liabilities | 12,149 | 5,817 |
| Total current liabilities | $91,406 | $71,006 |
| Operating lease liability, net of current portion | 61,750 | 70,221 |
| Liability related to the sale of future revenue | 15,000 | — |
| Other non-current liabilities[5] | 747 | 407 |
| Total liabilities | $168,903 | $141,634 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value — 200,000 and 100,000 shares authorized at September 30, 2025 and 2024, respectively; 60,631 and 58,877 shares issued and outstanding at September 30, 2025 and 2024, respectively | $— | $— |
| Additional paid-in capital | 1,793,163 | 1,715,119 |
| Accumulated other comprehensive loss | (627) | (522) |
| Accumulated deficit | (1,319,578) | (1,241,908) |
| Total stockholders’ equity | $472,958 | $472,689 |
| Total liabilities and stockholders’ equity | $641,861 | $614,323 |
[1]Including related parties' balances of $1.3 million and $0.5 million as of September 30, 2025 and 2024, respectively.
[2]Including related party balances of $0.3 million and $— million as of September 30, 2025 and 2024, respectively.
[3]Including related party balances of $53.9 million and $— million as of September 30, 2025 and 2024, respectively.
[4]Including related party balances of $1.8 million and $— million as of September 30, 2025 and 2024, respectively.
[5]Including related party balances of $0.2 million and $— million as of September 30, 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.